Positive results of this trial will open avenues for future research on HCC management using monotherapy or a combination of anticancer agents targeting MEK/ERK signaling pathway and other kinases involved in tumor growth and angiogenesis. Here, MAP2K7 is linked to hepatocellular carcinoma.